Cencora, Inc. COR is well-poised for growth on the back of a robust U.S. Healthcare Solutions business and product launches.

TimesSquare Capital Management, an equity investment management company, released its “U.S. Focus Growth Strategy” first quarter 2025 investor letter. A copy of the letter can be downloaded here.

TimesSquare Capital Management U.S. Focus Growth Strategy highlighted stocks like Cencora, Inc. (NYSE:COR), in the second quarter 2024 investor letter.Cencora, Inc. (NYSE:COR) sources and ...

Cencora Inc (COR) reports a 13% revenue increase and raises full-year guidance, driven by robust US healthcare solutions and strategic market positioning.

Cencora increases FY2025 EPS guidance to $15.70-$15.95 amid specialty growth May 07, 2025 10:57 AM ET Cencora, Inc. (COR) Stock AI-Generated Earnings Calls Insights Play ( 6min ) ...

Cencora Inc. (NYSE:COR), a leading player in the U.S. Healthcare Technology & Distribution sector, has been drawing significant attention from analysts due to its robust performance and strategic ...

Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their ...

Cencora ( (COR)) just unveiled an update. Cencora, Inc. reported significant growth in its fiscal 2024 results, boasting a 14.7% increase in fourth-quarter revenue to $79.1 billion and a 12.1% ...

Drug distributor Cencora has entered into a definitive agreement to acquire Retina ... "We are pleased to enter our next phase of growth with the support of a leading global pharmaceutical solutions ...

CONSHOHOCKEN, Pa. - Cencora, Inc. (NYSE: COR), a global pharmaceutical solutions provider with a market capitalization of $56.87 billion, announced the appointment of Lori J. Ryerkerk to its Board ...

Cencora, Inc. COR is well-poised for growth on the back of robust U.S. Healthcare Solutions business and product launches. However, intense competition is a concern. Shares of this Zacks Rank #3 ...